Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Assembly Biosciences, Inc./ S-8

SEC Filing · S-8

Assembly Biosciences, Inc.

ASMBNASDAQEQUITYCurrent

SEC Filing

Filed Aug 20, 2026Accepted Aug 20, 2026, 4:30 PM EDTCIK 1426800Accession 0001193125-26-359252
View company →Permanent SEC source ↗
Share

Company context

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesvirus, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.

Current securities

ASMBNASDAQ · EQUITY · Current

Recent company filings

  1. 8-K/A filingAug 14, 2026
  2. 10-Q filingAug 13, 2026
  3. Completion of Acquisition or Disposition of AssetsAug 13, 2026
  4. SCHEDULE 13G/A filingAug 13, 2026
  5. 4 filingJun 5, 2026

As-filed source

Primary evidence
As filedOpen full document ↗